208 related articles for article (PubMed ID: 32573886)
1. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
Das BB; Prusty BK; Niu J; Sue PK
Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.
Klimczak-Tomaniak D; Roest S; Brugts JJ; Caliskan K; Kardys I; Zijlstra F; Constantinescu AA; Voermans JJC; van Kampen JJA; Manintveld OC
Transplantation; 2020 Jul; 104(7):1508-1518. PubMed ID: 31644496
[TBL] [Abstract][Full Text] [Related]
3. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
6. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
[TBL] [Abstract][Full Text] [Related]
7. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis.
Zang S; Zhang X; Niu J; Das BB
Clin Transplant; 2023 Jan; 37(1):e14836. PubMed ID: 36259556
[TBL] [Abstract][Full Text] [Related]
8. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
9. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
Chatani B; Glaberson W; Nemeth Z; Tamariz L; Gonzalez IA
Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
[TBL] [Abstract][Full Text] [Related]
10. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
[TBL] [Abstract][Full Text] [Related]
11. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia.
Pizzo H; Shin B; Garrison J; Huang E; Malekzadeh M; Jordan SC; Puliyanda D; Toyoda M
Pediatr Transplant; 2021 Dec; 25(8):e14119. PubMed ID: 34390094
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
13. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
15. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir for the treatment of cytomegalovirus infections in pediatric intestinal transplant recipients: A case series.
Henry M; Leick M; Florescu DF; Keck M
Pediatr Transplant; 2021 Sep; 25(6):e14034. PubMed ID: 34081375
[TBL] [Abstract][Full Text] [Related]
17. Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients.
Ganapathi L; Blumenthal J; Alawdah L; Lewis L; Gilarde J; Jones S; Milliren C; Kim HB; Sharma TS
Pediatr Transplant; 2019 Nov; 23(7):e13568. PubMed ID: 31515909
[TBL] [Abstract][Full Text] [Related]
18. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.
Doesch AO; Repp J; Hofmann N; Erbel C; Frankenstein L; Gleissner CA; Schmidt C; Ruhparwar A; Zugck C; Schnitzler P; Ehlermann P; Dengler TJ; Katus HA
Drug Des Devel Ther; 2012; 6():289-95. PubMed ID: 23091373
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of valganciclovir prophylaxis in high-risk (D+/R-) renal transplant recipients experiencing delayed graft function.
Freedman SR; Ravichandran BR; Masters BM; Bromberg JS; Haririan A; Saharia KK; Heil EL; Sparkes T
Transpl Infect Dis; 2019 Aug; 21(4):e13125. PubMed ID: 31165548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
